Boothbay Fund Management’s Rein Therapeutics RNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$715K Hold
889,450
– – 0.01% 1162
2026
Q2
$925K Buy
+889,450
New +$1.08M 0.01% 1143
2022
Q3
– Sell
-13,937
Closed -$72K – 2664
2022
Q2
$72K Hold
13,937
– – ﹤0.01% 2038
2022
Q1
$143K Hold
13,937
– – ﹤0.01% 2009
2021
Q4
$157K Sell
13,937
-1,679
-11% -$26K ﹤0.01% 1574
2021
Q3
$319K Sell
15,616
-4,035
-21% -$88.4K 0.01% 1302
2021
Q2
$491K Buy
19,651
+2,070
+12% +$51.6K 0.02% 1013
2021
Q1
$503K Buy
+17,581
New +$602K 0.02% 943

Other funds holding RNTX

Boothbay Fund Management's RNTX Position: Q3 2026 in Review

Boothbay Fund Management held its Rein Therapeutics (RNTX) position steady in Q3 2026 at 889,450 shares worth $715K. The position accounts for 0.01% of the portfolio, ranked #1162.

Boothbay Fund Management first reported a position in RNTX in Q1 2021 and has held it in 8 quarters since. The position peaked at $925K in Q2 2026. 64 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.

  • Boothbay Fund Management held 889,450 shares of Rein Therapeutics worth $715K as of Q3 2026.
  • Boothbay Fund Management left its Rein Therapeutics share count unchanged in Q3 2026.
  • Rein Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q3 2026, its #1162 holding.
  • Boothbay Fund Management first reported a position in Rein Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • Boothbay Fund Management's Rein Therapeutics position peaked at $925K in Q2 2026.
  • 64 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.

Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.